文献速递痛风与晶体性关节病

非布司他逐步增量与秋水仙碱预防在降尿酸治疗初期预防痛风发作的疗效相当:FORTUNE-1 前瞻性多中心随机研究结果

Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study.
PubMed 文献 · Ann Rheum Dis · 2017-11-04

FORTUNE-1 前瞻性多中心随机开放标签研究纳入 255 例痛风患者,随机分为非布司他逐步增量组(A 组)、非布司他固定剂量联合秋水仙碱组(B 组)和非布司他固定剂量组(C 组),观察 12 周。A 组和 B 组痛风发作发生率均显著低于 C 组,但多重比较校正后差异无统计学意义;A 组与 B 组间无显著差异。

要点

  • 非布司他逐步增量组痛风发作率 20.8%,低于固定剂量组 36.0%,差异未达多重比较校正后显著。
  • 非布司他固定剂量联合秋水仙碱组痛风发作率 18.9%,低于固定剂量组 36.0%,差异未达多重比较校正后显著。
  • 逐步增量组与联合秋水仙碱组痛风发作率无显著差异。

核心结论

  • 数据提示非布司他逐步增量与低剂量秋水仙碱预防相比,在降尿酸治疗初期均可有效减少痛风发作。
  • 非布司他逐步增量可能成为低剂量秋水仙碱预防的有效替代方案。

研究设计与样本

  • 前瞻性、多中心、随机、开放标签、对照研究,共随机 255 例痛风患者,其中 241 例接受治疗。
  • 患者随机分为 A 组(非布司他从 10 mg/日逐步增量至 40 mg/日)、B 组(非布司他固定剂量 40 mg/日联合秋水仙碱 0.5 mg/日)和 C 组(非布司他固定剂量 40 mg/日),观察 12 周。
  • 痛风发作定义为因痛风症状使用非甾体抗炎药。

主要发现

  • 接受治疗患者中,痛风发作发生率 A 组为 20/96(20.8%),B 组为 18/95(18.9%),C 组为 18/50(36.0%)。
  • A 组与 C 组比较 P=0.047,B 组与 C 组比较 P=0.024,差异显著,但多重比较校正后差异无统计学意义。
  • A 组与 B 组痛风发作发生率无显著差异。

关键数值与推荐

  • A 组非布司他剂量从 10 mg/日逐步增量至 40 mg/日。
  • B 组非布司他固定剂量 40 mg/日联合秋水仙碱 0.5 mg/日。
  • C 组非布司他固定剂量 40 mg/日。
  • 观察期 12 周。
  • 痛风发作定义为因痛风症状使用非甾体抗炎药。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine whether febuxostat with stepwise dose increase is as useful as colchicine prophylaxis in reducing gout flares during the initial introduction of urate-lowering therapy in patients with gout in comparison with febuxostat with no dose titration. METHODS: In this prospective, multicentre, randomised open-label comparative study, patients were randomised to group A (stepwise dose increase of febuxostat from 10 to 40 mg/day), group B (fixed-dose febuxostat 40 mg/day plus colchicine 0.5 mg/day) or group C (fixed-dose febuxostat 40 mg/day) and observed for 12 weeks. Gout flare was defined as non-steroidal anti-inflammatory drug use for gout symptoms. RESULTS: A total of 255 patients were randomised, and 241 patients were treated. Among the treated patients, gout flares were experienced by 20/96 (20.8%) in group A, 18/95 (18.9%) in group B and 18/50 (36.0%) in group C. The incidence of flare was significantly lower in groups A and B than that in group C (P=0.047 and P=0.024, respectively), although the differences were not significant after correction for multiple comparisons. No significant difference was noted between the incidence of gout flare in groups A and B. CONCLUSIONS: Our data suggested that stepwise dose increase of febuxostat and low-dose colchicine prophylaxis effectively reduced gout flares in comparison with fixed-dose febuxostat alone. Stepwise dose increase of febuxostat may be an effective alternative to low-dose colchicine prophylaxis during the introduction of urate-lowering therapy. TRIAL REGISTRATION NUMBER: UMIN 000008414.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Yamanaka H, Tamaki S, Ide Y, et al. Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study. Ann Rheum Dis. 2017. PMID: 29102957. doi:10.1136/annrheumdis-2017-211574

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。